Exenatide Add-On to Continuous Subcutaneous Insulin Infusion Therapy Reduces Bolus Insulin Doses in Patients With Type 2 Diabetes: A Randomized, Controlled, Open-Label Trial
Diabetes Therapy - United States
doi 10.1007/s13300-016-0222-7
Full Text
Open PDFAbstract
Available in full text
Date
December 19, 2016
Authors
Publisher
Springer Science and Business Media LLC